Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-16T09:54:26.940Z Has data issue: false hasContentIssue false
  • English
  • Français

Adult ADHD and Comorbid Depressive Disorders: Diagnostic Challenges and Treatment Options

Published online by Cambridge University Press:  07 November 2014

David Goodman
Get access Rights & Permissions [Opens in a new window]

Extract

Attention-deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) are separately common mental health conditions that can have an adverse effect on a patient's quality of life if left untreated. These disorders frequently cooccur with one another, which can lead to increased patient suffering and diagnostic challenges for the treating clinician. In the United States adult population, epidemiological data show that the prevalence rate for MDD is 6.7%, while the ADHD prevalence rate in US adults is 4.4%. This epidemiological data represents the general population and likely underestimates the prevalence rates in clinic or practice patients. Examining the concurrent comorbid rate, if a patient has MDD, the likelihood of that patient also having ADHD is 18.6%; if the patient has ADHD, the likelihood of that patient having comorbid MDD is 9.4%. If the patient has dysthymia, the comorbid rate of ADHD is 12.8%, while those adults with ADHD have a comorbid rate of dysthymia of 22.6% (Slide 1).

The diagnostic distinction between ADHD and MDD is a critical aspect of clinical evaluation that often presents challenges and confusion to the treating clinician (Slide 2). There are several factors that clinicians should consider in order to best distinguish these disorders, and ensure an accurate diagnosis—age of symptom onset, presenting symptoms, and family history of either disorder.

Typically, ADHD presents first in children, whereas most mood disorders, specifically MDD, have their index case onset in adolescence. Although MDD and dysthymia is reported in childhood, the peak incidence occurs during the adolescent years. Thus, the age of onset becomes one diagnostic factor that can assist in distinguishing these two conditions.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 14 , Issue S6: Differential Diagnosis of Adult Attention deficit/Hyperactivity Disorder: Treatment Options and Comorbidity Considerations , July 2009 , pp. 5 - 7
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kessler, RC, Adler, L, Barkley, R, et al.The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–723.CrossRefGoogle ScholarPubMed
2.Kessler, RC, Berglund, P, Dernier, O, Jin, R, Merikangas, KR, Walters, EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.CrossRefGoogle ScholarPubMed
3.Kessler, RC, Berglund, P, Dernier, O, et al, and the National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.Google Scholar
4.Kessler, RC, Chiu, WT, Jin, R, Ruscio, AM, Shear, K, Walters, EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(4):415–424.Google Scholar
5.Merikangas, KR, Akiskal, HS, Angst, J, et al.Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543–552.Google Scholar
6.Birmaher, B, Brent, DA, Benson, RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1998;37(11): 1234–1238.CrossRefGoogle ScholarPubMed
7.Costelto, EJ, Mustillo, S, Erkanli, A, Keeler, G, Angold, A. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry. 2003;60(8):837–844.Google Scholar
8.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
9.Spencer, TJ, Adler, LA, McGough, JJ, Muniz, R, Jiang, H, Pestreich, L, and the Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380–1387.CrossRefGoogle ScholarPubMed
10.Biederman, J, Faraone, SV, Keenan, K, et al.Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch Gen Psychiatry. 1992;49(9):728–738.Google Scholar
11.Sana, S, Chant, D, Welham, J, McGrath, J. A systematic review of the prevalence of schizophrenia. PLoS Medicine. Available at: www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0020141. Accessed June 5, 2009.Google Scholar
12.Kessler, RC, Chiu, WT, Dernier, O, Merikangas, KR, Walters, EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627.Google Scholar
13.Pliszka, S and the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.CrossRefGoogle ScholarPubMed
14.Goodman, D. Treatment and assessment of ADHD in adults. In: Biederman, J, ed. ADHD Across the Life Span: From Research to Clinical Practice—An Evidence-Based Understanding. Hasbrouck Heights, NJ: Veritas Institute for Medical Education; 2006.Google Scholar
15.Sauer, JM, Long, AJ, Ring, B, et al.Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2004;308(2):410–418.Google Scholar
16.Capone, NM, McDonnell, T, Buse, J, Kochhar, A. Medication persistence among agents used to treat attention-deficit/hyperactivity disorder, diabetes, and elevated serum cholesterol. Poster presented at: 19th annual U.S. Psychiatric & Mental Health Congress; November 16, 2006; New Orleans, LA.Google Scholar
17.Safren, SA, Otto, MW, Sprich, S, Winett, CL, Wilens, TE, Biederman, J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. BehavHes Ther. 2005;43(7):831–842.Google Scholar
18.Solanto, MV, Marks, DJ, Mitchell, KJ, Wasserstein, J, Kofman, MD. Development of a new psychosocial treatment for adult ADHD. J Atten Disord. 2008;11(6):728–736.Google Scholar